Intensity Therapeutics(INTS) - 2025 FY - Earnings Call Transcript

Financial Data and Key Metrics Changes - The meeting confirmed that 10,989,589 shares of the company's voting capital stock were present, representing 59.73% of the outstanding voting stock [6][7] - The appointment of Eisner Amper LLP as auditors for the fiscal year 2025 was ratified with 10,922,860 shares in favor, 17,438 against, and 49,291 abstaining [12] Business Line Data and Key Metrics Changes - No specific data on business lines or key metrics was provided during the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting Company Strategy and Development Direction and Industry Competition - The company did not provide detailed insights into its strategy or competitive landscape during the meeting Management's Comments on Operating Environment and Future Outlook - Management indicated that remarks and responses would include forward-looking statements, cautioning that actual results may differ significantly from those discussed [14] Other Important Information - The meeting was conducted virtually to enhance stockholder access, and the agenda was made available for review [3] - The final results of the voting will be disclosed in a current report on Form 8-K within four business days of the meeting [13] Q&A Session All Questions and Answers Question: Were there any questions from stockholders? - No questions were received during the Q&A portion, leading to its closure [15]